Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB StudyJonathan W. Riess, David R. Gandara, Guillaume Luxardi et al.|JTO Clinical and Research Reports|2024Cited by 2